Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 9/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247728 | 0.94 | HDAC1 (0.74) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL9099931 | 0.94 | HDAC1 (0.74) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL28444240 | 0.94 | HDAC1 (0.74) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL11220445 | 0.94 | HDAC1 (0.74) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL10600882 | 0.94 | HDAC1 (0.74) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL6360257 | 0.90 | HDAC3 (0.72) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL19291326 | 0.87 | NPC1 (0.62) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL17902663 | 0.86 | L3MBTL1 (0.63) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL11584795 | 0.85 | HDAC3 (0.62) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL6638846 | 0.85 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC10HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115304506-B | Preparation method of secondary amide compound by activating primary amide through boron salt catalysis | 中国人民解放军国防科技大学 | 2023-11-14 | — | — | CN | disclosed |
| US-11731934-B2 | HDAC inhibitor compounds and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-116041199-A | Synthesis method of amide compound | 湖南中医药大学 | 2023-05-02 | — | — | CN | disclosed |
| CN-115974711-A | Preparation method of aryl amide compound by using aromatic ester catalytically activated by boron salt | 湖南农业大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-115304506-A | Preparation method of secondary amide compound by activating primary amide under catalysis of boron salt | 中国人民解放军国防科技大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20170174619-A1 | HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-06-22 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | HDAC3 843/4885HDAC1 1308/4885HDAC2 2021/4885 |
| US-20170174619-A1 | HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT | HDAC4, HDAC1, HDAC5 | HDAC3 4/4885HDAC1 2/4885HDAC2 5/4885 |
| US-11731934-B2 | HDAC inhibitor compounds and methods of treatment | HDAC4, HDAC1, HDAC5 | HDAC3 4/4885HDAC1 2/4885HDAC2 5/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | HDAC3 843/4885HDAC1 1308/4885HDAC2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.